Health ❯ Healthcare

Chronic Diseases

Diabetes Obesity Type 2 Diabetes Heart Disease Kidney Disease Hypertension Cardiovascular Disease Cardiovascular Diseases Cancer Diabetes Management

FDA Approves First Oral Weight-Loss GLP-1: Wegovy Pill to Launch in January

Trials show substantial weight loss with daily semaglutide pills, though a fasting intake requirement may challenge adherence.

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Large Swedish Study Finds ARBs Sustain the Best Long-Term Adherence in Hypertension

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Study Maps Alzheimer’s Hotspots in Rural Maryland With High Deaths, Low Diagnoses

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

WHO Endorses Long-Term GLP-1 Use for Obesity as Indian Ruling Opens Production and Safety Alerts Expand

New HIV Remission Case and Immunotherapy Trial Signal Immune-Based Paths Off ART

Monthly Tezepelumab Shot Lets Over Half With Severe Asthma Stop Daily Steroids, International Trial Finds

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

New Survey Finds Insurance Barriers Stalling Bariatric Surgery in India

Novo Nordisk Halts Phase-3 Alzheimer’s Trial of Semaglutide After Failure to Slow Decline

Antimicrobial Resistance Deepens as Experts Urge Smarter Prescribing and Non‑Antibiotic Care

AGA Overhauls Crohn’s Treatment With Living Guideline Favoring Early High‑Efficacy Therapies

UK Biobank Unveils Final Metabolomics Data on 500,000 People, Paving Way for Early Disease Risk Tests